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Abstract
The purpose of this paper is to examine the interactions between licensing status, equity issuance cycles,
and drug development success at the small pharmaceutical companies that originate these development
projects. Specifically, this paper is aimed at identifying how financing alternatives available to small
pharmaceutical companies influence development success and firm behavior. The hypotheses developed
and tested in this paper are as follows:
H 1: Pharmaceutical development projects that are licensed are more likely to advance to the next stage in
the clinical development process.
H2: A licensed pharmaceutical development projects' likelihood of advancing to the next stage of the
clinical development process will depend on the amount of equity issuance during the period in
which the project was licensed.
H3: Pharmaceutical development projects that are licensed during periods of low equity issuance are
more likely to advance to the next stage in the clinical development process than projects that were
not licensed or were licensed but not in a low equity issuance period.
H4: Pharmaceutical development projects that originate at firms that have multiple projects in
development at the beginning of a particular clinical trial stage are less likely to advance from phase
I to phase II, but more likely to advance in later stages.
H5: Pharmaceutical development projects that originate at firms that have previously launched a project
in the market are more likely to be launched in the market.
The results of a logistic regression analysis suggest that drugs licensed in periods of lowest equity
issuance exhibit a higher rate of advancement from phase II to phase III. The relationship between
advancement and amount of equity issuance at the time of licensing suggests that the lower the equity
issuance in the licensing period the more likely the drug will advance. These results point to the possible
existence of a "lemons" phenomenon in the market for pharmaceutical development projects. However, a
different interpretation of the results suggests that large pharmaceutical company licensees are superior
evaluators of quality and are perhaps more selective and opportunistically license higher quality drugs
when equity issuance is low and licensors have no other financing options. Both interpretations point to
the issue of information asymmetry as a central theme to this work.
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I Introduction
Drug development is the innovation engine of the pharmaceutical industry. As more is learned about
disease, new approaches are developed and investigated for targeting biological mechanisms in order to
create safer and more effective drugs. Understanding the factors that affect drug development is critical
for efficient development in the face of regulatory pressure, uncertain market conditions, low supply of
capital, and changing technology.
The industry has experienced a large increase in the number of license agreements in connection with
drug development over the last several decades. These license agreements have become an important
source of financing for small firms and a vital source of innovation for larger pharmaceutical companies.
The purpose of this paper is to examine the interactions between licensing status, equity issuance cycles,
and drug development success at the small pharmaceutical companies that originate these development
projects. Specifically, this paper is aimed at identifying how financing alternatives available to small
pharmaceutical companies influence development success and firm behavior. The hypotheses developed
and tested later in this paper are as follows:
Hl: Pharmaceutical development projects that are licensed are more likely to advance to the next stage in
the clinical development process.
H2: A licensed pharmaceutical development projects' likelihood of advancing to the next stage of the
clinical development process will depend on the amount of equity issuance during the period in
which the project was licensed.
H3: Pharmaceutical development projects that are licensed during periods of low equity issuance are
more likely to advance to the next stage in the clinical development process than projects that were
not licensed or were licensed but not in a low equity issuance period.
H4: Pharmaceutical development projects that originate at firms that have multiple projects in
development at the beginning of a particular clinical trial stage are less likely to advance from phase
I to phase II, but more likely to advance in later stages.
H5: Pharmaceutical development projects that originate at firms that have previously launched a project
in the market are more likely to be launched in the market.
The paper proceeds in section II with a background on the drug development process in the U.S. and
licensing agreements in the pharmaceutical industry. Theories about the managerial incentives,
information asymmetry, and financing strategy in relation to drug development are reviewed in section
III. Hypotheses about these relationships are formed in section IV and the methods utilized to test the
hypotheses are developed in section V. The results and discussion are presented in sections VI and VII,
respectively.
II Background on Pharmaceutical Development and Licensing
II.1 Pharmaceutical Development
Drug development is a highly regulated and structured process that often takes many years and costs
upwards of several hundred million to billions of dollars for a single approved pharmaceutical compound.
The process begins with drug discovery and progresses through preclinical testing, clinical development,
regulatory review and approval, and finally market launch. The focus of this paper is on drugs that
originate from US companies. Therefore, the description of the process below is based on the U.S. Food
and Drug Administration's regulations. However, the process is similar in most developed countries.
Drug Discovery
Drug discovery is the process by which chemical or biologic compounds are screened for potential
activity at a therapeutic target. Drug discovery can be divided into two basic approaches: compound-
centered and target-centered. The compound-centered strategy involves identifying compounds that
display physiological activity and then developing them for a specific therapeutic area or indication.
Many of the drugs developed through this approach are naturally occurring compounds, or synthetic
compounds that either mimic natural compounds or are analogues of human ligands.
The target-centered strategy starts with the identification of a physiological target that is known (or
hypothesized) to be of significance in a disease process. One or several of the following methods may
then be used to identify drugs that could potentially interact with the target: high-throughput screening,
combinatorial chemistry, structure-based design, in-silico modeling, computer algorithms, and vast drug
libraries.
The drug discovery phase may involve thousands of candidates while only a few may be selected to
proceed to lead optimization. Lead optimization is the process of screening and refining for toxicology
and pharmacokinetics. Lead optimization will typically involve testing with in vitro assays as well as
animal models.
Preclinical Development
The preclinical stage of drug development refers to the use of animal models of the disease to test for
physiologic activity of the drug candidate and pharmacodynamics, as well as to further refine
pharmacokinetics, drug distribution, and metabolism.
The distinction between drug discovery and preclinical is not universal. Some may describe everything
prior to clinical development as the preclinical stage, while others may uniquely define drug discovery,
lead optimization, and preclinical development as separate stages. More important than understanding the
semantics is to understand that it is often very difficult to obtain data on drug candidates before they
proceed to clinical development. Even though many of the practices in drug discovery and preclinical
development are regulated, companies are not required to make this information public and have little
incentive to do so in the preclinical stage.
Investigational New Drug Application
Prior to administering a xenobiotic compound to a human in a clinical trial, the sponsor of the trial must
apply to the U.S. Food and Drug Administration (FDA) by submitting an Investigational New Drug
Application (IND). Among other clinical and scientific data, the IND will contain background
information on the drug candidate, the results of preclinical testing, and the protocol to be used for the
administration to humans. The IND is reviewed by the FDA for medical, chemical, pharmacological,
toxicological, and statistical soundness. If no deficiencies are noted, the IND is approved and the sponsor
is allowed to proceed with clinical development.
Clinical Development
Once an IND is approved, the drug candidate can proceed into the clinical development phases, which is
notably distinct in that the testing takes place using human subjects. The regulatory and logistic aspects
of clinical trials are complex. The focus here will be on the purpose and differences of the sequential
phases of clinical development.
Clinical trials are carefully designed studies with prospective clinical endpoints. At the end of each
phase, the sponsor would review (with regulatory oversight) the results of the trial and its success in
meeting the endpoints to determine if the drug candidate should advance to the next phase. However, just
because a drug candidate was successful in a particular phase does not mean that it will advance further in
the development process. Changing market conditions, competitor dynamics, lack of resources, or a
change in strategic direction are just some of the reasons why a company may choose not to advance a
drug candidate.
Phase I
The purpose of a phase I trial is primarily to establish that the drug candidate is safe and tolerable. The
maximum tolerated dose, pharmacokinetic profile, toxicity, and adverse effects are studied in a relatively
small number of healthy subjects, usually less than 100.
Phase II
Phase II trials can involve several hundred human subjects and have multiple objectives. Phase II studies
usually consist of phase Ila and phase Ilb trials. A phase Ila trial is essentially a dose-ranging study in
diseased subjects where the desired outcomes are preliminary evidence of efficacy, effective range of
doses, and the optimum dose and dosing frequency. The pharmacodynamic profile of the drug candidate
is also investigated in a phase Ila trial. A phase Ilb trial seeks to establish a definitive dose-response
relationship and proof of efficacy in diseased patients. As in phase I trials, safety is monitored so that any
less common adverse effects might be detected with the larger number of subjects. Phase II trials are
usually blinded, placebo-controlled, and restricted to a well-defined study cohort.
Phase III
Phase III trials are conducted with a more general population of diseased subjects. The purpose is to
confirm efficacy in a large enough population that the results could reasonably be extrapolated to the
general population of patients who would receive the drug. Phase III trials also establish the complete
safety profile and serve as the basis for meeting regulatory guidelines and labeling requirements. Phase
III trials can involve thousands of patients with multiple treatment arms, and they are either placebo-
controlled or tested against a therapy with demonstrated efficacy. Sponsors are required to complete two
pivotal phase III clinical trials before submitting for regulatory approval.
New Drug Application & FDA Review
Following the successful completion of phase III, a sponsor can submit a New Drug Application (NDA)
to the FDA for review. The NDA contains all of the data obtained during development of the drug
candidate including information on manufacturing and quality control, package and labeling, nonclinical
pharmacology and toxicology, human pharmacokinetics, metabolism and bioavailability, clinical data,
patent information, etc. Depending on the proposed indication of the drug candidate, a review team at the
FDA is assigned to the NDA. Typical review times are between 6 months and a year. After reviewing
the NDA, the FDA will make a determination of approved, not approved, or approvable. A response of
"not approved" will be accompanied by a list of deficiencies and suggestions. However, a "not approved"
response usually means that new studies must be performed to correct the deficiencies and these NDAs
are typically abandoned. The drug candidate could still be developed for another indication by
undertaking new clinical trials to show efficacy for a different disease. An "approvable" response means
that some deficiencies were noted and the FDA requires more data before making a determination.
Market Launch
After receiving FDA approval the sponsor of the drug, or another entity that has marketing rights, may
begin manufacturing and selling the drug as a FDA-approved pharmaceutical. This requires
manufacturing, distribution, a sales force, marketing, and of course a demand for the drug to be used in a
clinical setting.
Cost of Development
The total cost of drug development is a disputed figure. Several studies have been conducted that place
the average total capitalized cost per approved drug in excess of a billion dollars. The mean cash outlay is
roughly $300 million for the clinical period of drug development (DiMasi, Hansen, and Grabowski 2003).
Large established pharmaceutical firms can use cash on hand or cash flows from product revenues to
finance drug development. Small firms, however, will require other financing options.
11.2 Licensing in the Pharmaceutical Industry
Licenses
A license agreement is a form of technology transfer in which the owner or rights holder of intellectual
property grants its use to the licensee. In the pharmaceutical industry, licensing of development stage
pharmaceutical technology takes place for many reasons. Not the least of which is the financial
compensation the licensor receives as a part of the deal.
As the cost of development increases in the later stages of clinical development, smaller companies often
cannot fund the development with resources on hand. Licensing allows the formation of strategic
alliances by formalizing the terms of the agreement. In addition to providing financial compensation to
the licensor, alliance partners can often provide resources to aid in the development (financial, human
capital, expertise, etc.), manufacturing capabilities, or commercial capabilities such as marketing and
distribution (Mendes 2005).
Licensees seek access to these pharmaceutical development projects as an alternative to investing in their
internal R&D capabilities. A licensee may be interested in exploiting the technology in a different field
of application as the licensor. A licensee may also be looking to diversify their investments in drug
development and see a strategic alliance or in-license of a project as an appropriate way to manage their
risk.
Strategic Alliances
In the pharmaceutical industry, strategic alliances generally come in two varieties: co-development
agreements and co-marketing agreements. Under a co-development agreement a licensor grants to the
alliance partner rights to exploit the technology. Together the licensor and licensee jointly develop the
technology. Typically, a licensee will pay the licensor an upfront fee followed by milestone payments
and royalties. The milestone payments are usually payable upon successful completion of clinical trials,
regulatory filing, approval, product launch, or some combination of these. This arrangement gives the
licensee access to the technology at a reasonable upfront cost, aligns the incentives for successful
development of the drug, and gives the licensor partial benefits of the upside. The licensor can contribute
to the further development of the pharmaceutical and influence the likelihood of success. Both parties
will capture value as the project successfully advances through the development process.
Co-marketing agreements are similar to co-development agreements. The licensor and licensee can both
contribute to the marketing and sale of a developed pharmaceutical. The two parties may have access to
different geographic areas or provide complementary functions, i.e. manufacturing, distribution, sales, or
other commercial roles. Again, both parties contribute and create a larger potential upside (Mendes
2005).
A license agreement is necessary for both types of strategic alliances to establish the terms and to allow
both parties to exploit the intellectual property and benefit from the arrangement.
11.3 Financing Alternatives
A pharmaceutical firm may have several options for financing its pharmaceutical development projects.
Large established firms with significant revenues can fund R&D projects with cash flows from marketed
projects. Also, these cash flow positive firms with established financial history can more easily access
capital markets should they need to.
Small firms, on the other hand, are more constrained in their financing options. Private companies,
primarily financed by venture capital or private equity, may only have enough cash to finance phase I and
small phase II clinical trials. Therefore, these firms' ability to successfully demonstrate value early in the
development process is crucial to their ability to raise follow-on financing. The investors in these
companies will look to exit their investments through initial public offering in the equity markets or
acquisition by another pharmaceutical company. Similarly, small publicly traded pharmaceutical
companies often have no significant revenue from product sales and they may have cash reserves that
only allow them to execute on a small number of early phase clinical trials. Both private and small public
firms will seek licensing agreements or strategic alliances in order support their continued operations and
development projects.
III Theory
Due to the structure and regulation of pharmaceutical development, the industry has been a testing ground
for economists and other academics for decades. There is a plethora of literature written using the
pharmaceutical industry to test many theories related to the topic of this paper. A few of these papers are
presented below to establish a foundation for the creation of the model defined below.
III.1 Licensing as a Sign of Project Quality
It has been demonstrated that alliances send a positive signal to capital markets and result in higher
valuations of the licensor after these alliances have been formed (Nicholson, Danzon, and McCullough
2005). The large pharmaceutical company licensees in these alliances validate the development projects
simply by forming the alliance.
Extrapolating this concept to include all license agreements on a drug, any license agreement on a
pharmaceutical development project can be considered a signal of quality. Licensees will carefully
evaluate a project prior to a license agreement. These licensees may have a greater ability to judge the
quality and value of a project than investors in public markets or venture capital. Therefore, it is assumed
that any license on a project is a positive signal of quality.
111.2 Information Asymmetry
There is inherent information asymmetry in drug development. The originator of a development project
is in a better position to judge the quality of the project than financial intermediaries and public markets.
However, large pharmaceutical companies may be superior evaluators of the quality of a project as
evidenced by the positive signal resulting from a license agreement. This information asymmetry can
impact firm behavior. An originator will form views on the quality of their own development projects
and the firms' incentives will affect how this information is conveyed to investors and potential licensees
(Nicholson, Danzon, and McCullough 2005).
Information asymmetry and incentives are especially important for small firms. Small firms may only
have a few development projects and the success of these projects will determine the future of the
company and its employees. Assuming a company can accurately determine the quality of its
development projects, this information will impact the company's behavior. For example, if a firm
determines the quality of a project to be high and therefore its likelihood of success to also be high, the
firm will be more likely to continue the development of the project and will seek to finance it in a manner
that allows it to capture the most value. On the other hand, if a project's quality is perceived to be low,
the firm will be incentivized to monetize the project early by licensing it to another firm.
In reality, a firm cannot determine the quality of a development project with complete certainty.
Therefore, it will seek a strategy that allows it to maximize value and minimize risk. In doing so, the firm
may take advantage of the information asymmetry.
111.3 Access to Capital Markets and Financing Decisions
Capital markets will cycle through periods of high and low accessibility as a function of macroeconomic
conditions and other industry events. These cycles influence how firms will invest in development
projects and how they will choose to finance these projects. These cycles also influence the behavior of
other financing intermediaries. Venture capital investors' ability to exit investments depends on the
accessibility of capital markets. Larger pharmaceutical companies' ability to issue debt or equity to
support an acquisition is also affected by capital market cycles.
When a small firm has a choice in how it finances its development projects, it will seek a strategy that
maximizes value and promotes the continued operation and existence of the company. When a firm has
access to equity capital markets and the cost of equity is low, it will choose to finance high value projects
with equity so that it can capture more value. It will choose to divest low value projects by licensing
them to other firms. However, when access to equity markets is limited and the cost of equity is high, a
small, capital-constrained firm will be forced to seek suboptimal financing strategies. This means that a
firm will license more high quality projects in order to support their development while giving up a
portion of the upside.
Other studies have focused on the limited bargaining power of small firms during periods of low equity
issuance. They state that lower bargaining power translates to more property rights assigned to the
licensee in a strategic alliance (Lerner, Shane, and Tsai 2003). The less property rights at the originating
firm leads to lower success rates in the development process (Higgins 2007). Therefore, these studies
conclude that strategic alliances formed during periods of low equity issuance are therefore less
successful. However, for the purposes of this paper property rights in the license agreement are not
observed and it is assumed that any license on a project is a vote of quality.
III.4 Internal Capital Markets and Managerial Incentives
It has been shown that small-portfolio firms are more likely to advance projects from phase I to phase II
but less likely to advance after that. This suggests that managerial incentives influence the decisions to
take a project forward in the clinical development phase (Guedj and Scharfstein 2008). A firm with
several projects will have a more efficient internal capital market and resources will be diverted from low
quality projects to high quality projects. However, if a firm has very few development projects it will be
less likely to abandon low quality projects.
111.5 Validation From Previous Product Launch
Because of the effects of information asymmetry and managerial incentives at small firms and the length
of time it takes to successfully develop and launch a pharmaceutical, a firm could originate and license
several low quality projects before there is a shift in information asymmetry. Firms that originate high
quality projects would ultimately be validated once a project is successfully developed and launched in
the market. Therefore, it could be expected that projects originating from firms which have originated
previously launched projects are of higher quality and should be more likely to advance in the
development process. Having previously originated a launched project is regarded as a signal of quality
for the firm.
IV Hypotheses
The following hypotheses follow from the theory section above.
IV.1 Effect of Licensing Status
Pharmaceutical development projects that are licensed are more likely to advance to the next stage in the
clinical development process.
H1: P(ivt>to > (t lIto n At, = 1) > P( )vt>to > t I to n At,, = 0)
1 Phase I
D 2 Phase II
3 Phase III
4 Launch
The subscript to indicates the reference date for each project. The reference date is the earliest date that
the project initiated a clinical trial of a given phase. For instance, the earliest date that a particular project
started a phase I trial will be its to for the phase I data set. The variable D indicates the clinical trial
phase. The term cDvt>to > Oto therefore refers to the advancement of the project to a subsequent phase.
IV.2 Effect of Equity Issuance at Time of First License
A licensed pharmaceutical development projects' likelihood of advancing to the next stage of the clinical
development process will depend on the amount of equity issuance during the period in which the project
was licensed.
H2: P(vt>to > ct 0 1 to n Ato = 1) = f (EI(Qt))
EI(QtL) = f Equity Issuancepharma Index(t)dt I q0 < tL < q1
The EI(QtL) function is the amount of equity issuance in the pharmaceutical industry for a given quarter.
IV.3 Effect of First License in a Low Equity Issuance Period
Pharmaceutical development projects that are licensed during periods of low equity issuance are more
likely to advance to the next stage in the clinical development process than projects that were not licensed
or were licensed but not in a low equity issuance period.
H3: P(clvt>to > ctolIto n EtL = > P(t>to > to I o n EtL = 0)
EtL = 1  EI(QtL)< EIthreshold
10 otherwise
The EtL variable is a transform of the equity issuance at the time the project was first licensed from a
continuous variable to a binary variable where an arbitrary threshold value was used to define a low
equity issuance period.
IV.4 Effect of Simultaneous Development Projects at an Originator
Pharmaceutical development projects that originate at firms that have multiple projects in development at
the beginning of a particular clinical trial stage are less likely to advance from phase I to phase II, but
more likely to advance in later stages.
H4a: P(Ivt>to > to lcto = 1 n Et. = 1) < P(clvt>to > Oto lcto = 1 n rto = 0)
H4b: P(tvt>to > (to lDto > 1 n Fto = 1) > P(Dvt>to > dto ldto > 1 n Fto = 0)
1  Zj Tij > 1 VrijlIto (rij) < 4
4 0 otherwise
The Fi,to variable indicates whether there are concurrent development projects at time to at the same
originating company i as project rj. The subscript i indexes a particular company and the subscriptj
indexes a particular development project with reference date to.
IV.5 Effect of Previously Launched Projects at an Originator
Pharmaceutical development projects that originate at firms that have previously launched a project in the
market are more likely to be launched in the market.
H5: P(clvt>to > Oto It Or n Fto = 1) > P(Ivt>to > dto IlOto n Fto = 0)
= 1 Zj r; > 0 Vrij|Ito (rij) = 4
' 0 otherwise
V Data and Methods
V.1 Description of datasets
The Pharmaprojects database was used to identify all pharmaceutical development projects originating at
U.S. companies. The data was separated into sets based on clinical trial phases. Three separate data sets
were created for every project that initiated a phase I, phase II, or phase III clinical trial. Phase I/II and
phase II/III projects were treated as phase I and phase II projects, respectively. The date of the earliest
instance of a clinical trial in the given phase was used as the reference date to obtain the market
capitalization value from Factset, a financial markets database. Using market capitalization data, and
information from CapitalIQ and Bloomberg, the projects in each of the three clinical trial phase data sets
were separated between public and private companies on the reference date. For the public companies,
the market capitalization was inflation adjusted to 2011 dollars. A cutoff of an inflation-adjusted $2
billion market capitalization was used to restrict the analysis to small public companies. This resulted in
six unique data sets: a private company subset and a small public company subset for each of the three
clinical trial phase data sets. These data sets were further filtered for projects that had recent reference
dates but no subsequent clinical trial in a later phase (within 2 years for phases I and II, and three years
for phase III) and for projects that were indicated as having been licensed but did not have an associated
licensing date. Projects that originated at organizations other than traditional pharmaceutical or
biotechnology companies were also excluded (e.g. not-for-profit organizations or academic institutions).
This left a total of 1,738 unique pharmaceutical development projects with 1,117 observations for phase I,
828 observations for phase II, and 371 observations for phase III. Figure 1 displays the summary
statistics for the six datasets.
Low Equity Issuance Periods
The EtL variable, as previously defined, is a binary variable given the value of 1 to indicate that on the
reference date to (the date associated with the earliest trial of a given phase) the project was licensed and
also that the license date tL occurred in a period of low equity issuance.
Periods of low equity issuance were determined using the Bloomberg United States Pharmaceutical Index
(BUSPHRM:IND). All equity issuances from index companies since 1989, the year of the earliest license
in the dataset were summed into quarters. These values were inflation adjusted and a moving average for
each quarter was taken over the current quarter and the previous three. Then, based on the date of the
earliest license on a pharmaceutical project and the amount of averaged equity issuance in that quarter,
that project was defined as being licensed in a low equity issuance period or not. This confined the
analysis to those licensing characteristics which were only observable on the reference date. The graph of
equity issuance and number of first licenses appears in Figure 2.
The threshold value for defining periods of low equity issuance was chosen to be $1,200 million. This
put approximately a third of the equity issuance periods in the low equity issuance category.
The Pharmaprojects database was used to calculate the other regression variables as previously defined.
V.2 Model
Logistic Regression Analysis
For each project that started a given phase of clinical trials, AJ(ct 0) was defined as a dependent binary
variable that measures advancement of the project to the subsequent phase of development. The variable
took the value of 1 if there was a subsequent clinical trial in a later phase, and 0 otherwise.
Ag ( Io = ovt>to > Oto l Oto= otherwise
Based on the theory and hypotheses, it follows that the probability of advancing to a subsequent stage of
clinical trials is a function of the licensing status, the level of equity issuance at the time of the first
license, the number of current development projects at the same originating firm, and the number of
previously launched projects at the originating firm.
PAdv = P (Ai(('to)) = P(clvt>to > Pto IDto) = f (Ato, EtL, Fi,to, Hi,to)
Logistic regression will be employed to investigate the effect of these variables on the probability of
advancing to a subsequent phase of clinical development.
Since Ato , EI(Qt), and EtL are related variables, i.e. they are all related to the licensing status, three
logistic regression models were be used to test HI, H2, and H3 in order to prevent confounding factors.
Testing of HI simply involves investigating the effect of licensing status at the commencement of a
clinical trial phase on the probability of advancement to a subsequent clinical trial.
logit(PAd,) = a + AAto + yri,to + ili,to + fl Control Variables
In order to test H2, the datasets were limited to only those projects that were licensed on the reference
dates. Then a regression with EI(QtL) as an independent continuous variable was performed.
logit(PAd,) = a + puEI(QN) + yri,to + rni,to + # Control Variables
The regression model for H3 uses the binary variable EtL to indicate that the project was licensed in a low
equity issuance period.
logit(PAd,) = a + EEtL + yri,to + Tni,to+ Control Variables
H4 and H5 were tested by including rito and lHte in each of the three models.
Controlling for Potential Market Size, Therapeutic Area, Reformulations, and Biologics
The Pharmaprojects database contained information on potential market size, therapeutic area, drug
reformulations, and biologics. Control variables using this information are described below.
Market Size
Pharmaprojects assigns Market Size Ratings to each of the projects as follows:
The rating is based on the reported worldwide sales for its primary therapeutic category. The five bands
of sales value are as shown:
1 $0 - $500 million
2 $501 - $2,000 million
3 $2001 - $5,000 million
4 $5001 - $10,000 million
5 $10,000 million or greater
A score of 0 is shown where a market size value is not applicable.
The market size data has been collected from a variety of reputable sources (e.g. analysts, industry
reports, and company information) and means are calculated to place each therapeutic classification
within a band. The ratings were independently verified and are under constant review.
Dummy variables were defined for the market size ratings combining categories 4 and 5 into Market Size
High and combining categories 2 and 3 into Market Size Mid. An important note on the Market Size
Ratings: the rating values read from the Pharmaprojects database are the current ratings on the date the
database was accessed and not necessarily the same rating that the project had on the reference date.
Therapy Codes
The Pharmaprojects database includes primary therapy codes for each project. The broad categories for
these therapy codes appear below:
A Alimentary/Metabolic
B Blood/clotting
C Cardiovascular
D Dermatological
F Formulations
G Genitourinary and Sex Hormones
H Hormones excluding Sex Hormones
I Immunological
J Anti-infective
K Anticancer
M Musculoskeletal
N Neurological
P Antiparasitic
R Respiratory
S Sensory
T Biotechnology
V Miscellaneous
If a primary therapy code was defined as Formulations or Biotechnology, then the most obvious of the
other assigned Therapy Codes was chosen as a replacement for the analysis. TherCode was defined as a
categorical variable for each project for the regression analysis.
Reformulation
The Formulation section covers novel reformulations of existing drugs, generally using novel
technologies, and also including novel fixed-dose combinations.
Since these are reformulations of existing drugs, the safety and efficacy profiles should be well
understood and one would expect that they experience a higher success rate in advancing to subsequent
phases.
If the primary therapy code is lasted as Formulation, then a Formulation dummy variable took a value of
1 and the most prominent or obvious therapy code was then chosen to replace it for the TherCode
categorical variable described above. Pharmaprojects describes the Formulation category as follows:
Biologic
The Pharmaprojects database also has a Biotechnology therapy code category. If any therapy code
describing a project was the Biotechnology category, then the dummy variable Biologic took a value of 1.
The Biotechnology classes on Pharmaprojects cover all drugs involving:
- Recombinant proteins/peptides/vaccines (including biosimilars)
- DNA/RNA-based therapeutics (gene therapies or oligonucleotides)
- Monoclonal antibodies and their conjugates/fusions/derivatives
- Advanced therapeutic cell cultures (e.g. stem cells)
VI Results
The regression results are presented in Figures 3 through 14. Regressions were performed adding new
variables in each column. Columns A through E in Figures 3 through 8 show the results using Ato, the
licensing status, as an independent variable. Columns F through J use EtL, the variable indicating that the
project was licensed in a low equity issuance period. Columns B and G add Fito the variable indicating
simultaneous development projects at the originating firm. Columns C and H add Ikto the variable
indicating previously launched projects that originated at the same firm. Columns D and I add the market
size control variables and columns E and J add the therapy code control variables.
Figures 9 through 14 show the regression results for licensed projects using EI(QtL), the amount of
equity issuance at time of licensing as an independent continuous variable.
VI.1 Review of Hypotheses
Hypothesis 1
The licensing status of a project Ato is associated with an increased likelihood of advancement to the next
phase of clinical trials. In all of the results, the odds ratio for the A coefficient is greater than 1 and ranges
between 1.16 and 3.37. The most significant results for licensing status occur for phase II to phase III
advancement probabilities at small public companies (Figure 6 columns A through E) where the p-values
were less than 10%. All other datasets failed to produce significant results. Therefore, H 1 cannot be
accepted with statistical significance.
Hypothesis 2
The amount of equity issuance at the time of licensing for licensed projects did not produce consistent
results across the datasets. For phase II to phase III advancement at private companies (Figure 11) and
phase III to launch advancement at public companies (Figure 14) the results were significant and in the
predicted direction as indicated by the negative coefficient. For these data sets, an increase in the amount
of equity issued during the period in which the project was first licensed results in a decrease in likelihood
of advancement to the next stage. Hypothesis 2 can be accepted with statistical significance but limited to
these datasets.
Hypothesis 3
A project licensed in a low equity issuance period also experiences an increased likelihood of
advancement for most of the datasets. The most significant results were for the phase II to phase III
advancement probabilities at both private and small public companies (Figures 5 and 6 columns F through
J). The advancement from phase III to launch at small public companies also produced statistically
significant results (Figure 8 columns F through J). Hypothesis 3 can be accepted with statistical
significance for phase II to phase III advancements and phase III to launch at small public companies.
Hypothesis 4
The existence of concurrent development projects at a firm did not appear to significantly influence the
probability of advancement. In the single dataset where the ft0 variable approached statistical
significance (Figure 5), the coefficient indicated that the effect was in the opposite direction predicted in
hypothesis 4. Therefore, hypothesis 4 is rejected.
Hypothesis 5
Previously launched projects from the originating firm did not have an effect in the earlier stages of
clinical development. However, for phase III to launch advancement at small public companies the effect
was statistically significant with an odds ratio ranging between 2.22 and 2.62. Hypothesis 5 is accepted
for the phase III to launch for the small public companies dataset.
VI.2 Effect of Control Variables
In general, the inclusion of the variable to control for market size and therapy code did not seem to greatly
impact the results. Furthermore, since Pharmaprojects uses the therapy code in assigning the potential
market size, there could be a confounding factor when including these variables in the regression analysis.
VII Discussion
VII.1 Information Asymmetry and "Lemons"
One interesting result of the regression analysis is that a license alone does not appear to have a great
effect on the likelihood of advancement. However, the drugs that were licensed in the periods of lowest
equity issuance do exhibit a higher rate of advancement from phase II to phase III. The relationship
between advancement and amount of equity issuance during the licensing period as shown in figures 11
and 14 would suggest that the lower the equity issuance in the licensing period the more likely the drug
will advance. These results point to the possible existence of a "lemons" phenomenon in the market for
pharmaceutical development projects (Pisano 1997). When these small firms have the ability to finance
their higher quality projects through non-licensing means, they are more likely to license their lower
quality projects. When licensing is the only option to finance development, they license out both their
high and low quality projects.
There is, however, a different interpretation of these results. Since large pharmaceutical company
licensees are superior evaluators of quality, perhaps they are more selective and opportunistically license
higher quality of drugs in a buyers' markets, i.e. when equity issuance is low and licensors have no other
option for financing development. Both interpretations point to the issue of information asymmetry as a
central theme to this work.
Also worth noting are the relative significance of the phase II to phase III advancement results. Generally,
the regression results for these datasets produced statistically significant results and the coefficients were
of greater magnitude. This could be related to the characteristics of phase II trials. Phase II clinical trials
are usually the first studies in which drug candidates are given to actual diseased or afflicted subjects.
Efficacy is observed for the first time in human beings. Phase II trials also tend to exhibit the highest
failure rates relative to the other phases. If successful, the results of these trials provide the first proof of
concept for the drug.
It may be the case that the information asymmetry is highest going into a phase II trial. Also, the ability
to determine the quality of a project may not be a linear function of the absolute quality of the project.
Drugs with the highest quality may be readily identified as high quality and easily licensed. As the
absolute quality of a drug decreases even slightly, it may become very difficult to observe the quality of
the drug. Therefore, drugs that are of lower quality on an absolute scale but have relatively different
quality may be perceived as having similar quality. Licensors may be more likely to wait for a correction
of the information asymmetry following the phase II results before pursuing a license agreement.
VII.2 Limitations
There are several limitations to this research. The first limitation is that the date of the first license is used
as the reference date for licensing. It is possible that license agreements are terminated or renegotiated.
Terminated projects may be re-licensed at later dates. Another potential criticism is that the terms and
property rights assigned in the license agreements are not observable in the Pharmaprojects database. It is
possible for a drug to be non-exclusively licensed and the relative property rights assigned in each license
could make one license agreement a better signal of quality than another. Without the ability to observe
the details of the license agreement it is difficult to ascertain which license agreement is most relevant for
this study if a single project has multiple license agreements.
License agreements may also result indirectly from unrelated corporate action, e.g. an acquired company
or subsidiary may license an entire portfolio of projects to the acquirer or parent organization. Licenses
under these types of situations may create data points that are not appropriate or relevant to this study.
Over the course of the sample period there have been many changes in the pharmaceutical industry that
are not controlled for in the analysis. The impact of regulatory changes could impact development
strategy, capital markets, likelihood of success, cost, and value of a project. Scientific advancements and
increased biological/physiological knowledge have led to significant changes in drug discovery and
development. Additionally, over the course of the sample period there have been changes in the structure
of licensing deals (e.g. milestone payments, royalties, assignment of property rights between licensor and
licensee, etc.) that may affect the analysis.
Perhaps the most important changes over this period are the rapid rise in clinical trial costs (DiMasi et al.
2007 and 2003) and the increased risk of regulatory rejection. The rise in clinical trial costs has
accelerated and quickly outgrown the amount of capital readily available to finance these developments.
This has put extreme pressure on the drug development process and specifically on small resource-
constrained companies. This makes licensing much more attractive than independently developing the
drug. A likely effect is that potential licensees have therefore approached licensing with increasing
scrutiny and caution. This should therefore cause a shift in the information asymmetry problem over the
course of the analysis.
The limitations discussed here indicate that the results of the analysis should be interpreted with caution.
However, the limitations discussed herein also present opportunities for future work in this area.
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IX Figures
Figure 1: Descriptive Statistics of Datasets
The descriptive statistics below are the mean values for the binary variables used in the regression
analysis. The mean of A (<ptP) gives the percentage of projects that advanced to the next phase. The
mean of At. gives there percentage of projects that were licensed at the initiation of the specific phase of
clinical trials. The mean of Et gives the percentage of projects that were licensed in a low equity
issuance period at the initiation of the specific phase of clinical trials. The mean of i,to gives the
percentage of projects that were originated at firms with concurrent projects at the initiation of the
specific phase of clinical trials. The mean of 1-li,t gives the percentage of projects that were originated at
firms that had previously launched projects at the initiation of the specific phase of clinical trials. The
mean values for the control variables MS-Mid, MS-High, Formulation, and Biologic are also presented.
The number of observations refers to the number of projects that were included in each dataset. Many of
the projects were included in multiple datasets and the total number of unique projects is also provided.
Phase I 44.4% 10.8% 2.4% 90.9% 19.3% 67.1% 18.4% 17.9% 30.1% 1,117
Private 45.7/ 8.6% 1.5% 83.6% 12.9% 64.2%a 20.3% 17./6 26.2%/ 536
Small Public 43.2% 12.9% 3.3% 97.6% 25.3% 69.2% 16./6 18.1% 33.2% 581
Phase II 25.2% 15.2% 3.6% 90.7% 21.1% 65.0% 19.7% 23.4% 24.3% 828
Private 22.0% 13.9% 2.5% 84.8% 14.9% 62.0% 23.0% 26.8% 21.3% 395
Small Public 28.2% 16.4% 4.6% 96.1% 26.8% 67.7%/ 16.6% 20.3% 27.0% 433
Phase III 16.7% 27.2% 9.2% 86.3% 26.7% 59.0% 21.0% 23.5% 31.0% 371
Private 15.4% 19.2% 4.6% 75.4% 23.9% 60.8% 22.3% 20.8% 16.9% 130
Small Pubhc 17.4% 31.5% 11.6% 92.1% 28.2% 58.1% 20.3% 24.9% 38.6% 241
Number of unique projects included in analysis 1,738
Figure 2: Number of First Licenses and Equity Issuance by Quarter
The chart below displays the number of first licenses in each quarter calculated from the Pharmaprojects
database. The amount of moving average of equity issuance from the Bloomberg United States
Pharmaceutical Index (BUSPHRM:IND) is plotted in millions of dollars and inflation adjusted to 2011.
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Figure 3
Logistic regression results for Phase I to Phase II advancement for projects originating at private
companies using licensing status Ato and licensing in low equity issuance period EtL as independent
variables.
Figure 3
A B C D E F G H I J
0.28 0.29 0.28 0.26 0.23
[S.E.] [0.31] [0.31] [0.31] [0.31] [0.33]
p-value 0.359 0.354 0.361 0.400 0.473
Odds Ratio 1.33 1.33 1.33 1.30 1.26
S 1.29 1.30 1.29 1.46 1.37
[S. E.] [0.82] [0,82] [0.82] [0.82] [0.85]
p-value 0.117 0.115 0.116 0.077 0.105
*
Odds Ratio 3.63 3.65 3.64 4.30 3.95
Y 0.07 0.08 0.16 0.10 0.08 0.08 0.17 0.11
[S.E.] [0.23] [0.24] [0.24] [0.25] [0.24] [0.24] [0.24] [0.25]
p-value 0.756 0.751 0.518 0.690 0.737 0.731 0.489 0.657
Odds Ratio 1.08 1.08 1.17 1.10 1.08 1.08 1.18 1.12
T -0.02 -0.04 0.04 -0.03 -0.04 0.04
[S.E.] [0.26] [0.27] [0.28] [0.26] [0.26] [0.28]
p-value 0.933 0.876 0.896 0.922 0.874 0.875
Odds Ratio 0.98 0.96 1.04 0.97 0.96 1.04
P MS-Mid -0.10 -0.03 -0.08 -0.01
[S. E.] [0.25] [0.29] [0.25] [0.30]
p-value 0.692 0.906 0.742 0.973
Odds Ratio 0.91 0.97 0.92 0.99
P MS-tHgh 0.68 0.54 0.73 0.58
[S.E.] [0.30] [0.37] [0.30] [0.37]
p-value 0.023 0.143 0.016 0.113
** **
Odds Ratio 1.98 1.71 2.07 1.79
P Formulation -0.07 -0.06
[S.E.] [0.26] [0.26]
p-value 0.785 0.806
Odds Ratio 0.93 0.94
6 Bio/ogic -0.10 -0.07
[S.E.] [0.22] [0.22]
p-value 0.663 0.749
Odds Ratio 0.91 0.93
TherCodes N N N N Y N N N N Y
a intercept -0.20 -0.26 -0.26 -0.40 0.34 -0.19 -0.26 -0.25 -0.42 0.28
[S.E.] [0.09] [0.22] [0.22] [0.30] [0.43] [0.09] [0.22] [0.22] [0.30] [0.43]
p-value 0.030 0.235 0.239 0.193 0.435 0.030 0.236 0.239 0.166 0.514
** **
Pseudo R2  0.001 0.001 0.001 0.018 0.045 0.004 0.004 0.004 0.022 0.049
Wald p-value 0.092 0.180 0.300 0.009 0.076 0.038 0.084 0.160 0.003 0.047
Observations 536 536 536 536 536 536 536 536 536 536
Significance Code: **** 0.1%; *** 1%; ** 5%; * 10%
Figure 4
Logistic regression results for Phase I to Phase II advancement for projects originating at small public
companies using licensing status At0oand licensing in low equity issuance period Et, as independent
variables.
Figure 4
A('to = 1) A B C D E F G H I J
0.22 0.22 0.23 0.23 0.20
[S.E.] [0.25] [0.25] [0.25] [0.25] [0.26]
p-value 0.369 0.367 0.366 0.366 0.445
Odds Ratio 1.25 1.25 1.25 1.25 1.22
-0.05 -0.05 -0.04 -0.04 0.11
[S.E.] [0.47] [0.47] [0.47] [0.47] [0.49]
p-value 0.922 0.923 0.926 0.938 0.827
Odds Ratio 0.95 0.96 0.96 0.96 1.11
Y 0.05 0.07 0.08 0.24 0.01 0.03 0.04 0.21
[S.E.] [0.55] [0.55] [0.55] [0.57] [0.55] [0.55] [0.55] [0.57]
p-value 0.926 0.905 0.884 0.670 0.982 0.960 0.941 0.712
Odds Ratio 1.05 1.07 1.08 1.28 1.01 1.03 1.04 1.24
Tt -0.13 -0.13 -0.07 -0.13 -0.13 -0.06
[S.E.] [0.19] [0,19] [0.20] [0.19] [0.19] [0.20]
p-value 0.496 0.494 0.747 0.499 0.497 0.756
Odds Ratio 0.88 0.88 0.94 0.88 0.88 0.94
SMS-Mid -0.01 -0.27 0.00 -0.25
[S.E.] [0.25] [0.31] [0.25] [0.31]
p-value 0.962 0.392 0.996 0.418
Odds Ratio 0.99 0.77 1.00 0.78
P MS-High 0.10 -0.50 0.11 -0.48
[S.E.] [0.30] [0.41] [0.30] [0.41]
p-value 0.749 0.225 0.722 0.242
Odds Ratio 1.10 0.61 1.11 0.62
P Formulation -0.89 -0.91
[S.E.] [0.27] [0.27]
p-value 0.001 0.001
*** *4*
Odds Ratio 0.41 0.40
P Bio/ogic -0.55 -0.55
[S.E.] [0.19] [0.20]
p-value 0.005 0.005
Odds Ratio 0.58 0.58
TherCodes N N N N Y N N N N Y
a intercept -0.30 -0.35 -0.33 -0.36 -0.03 -0.27 -0.28 -0.27 -0.30 0.02
[S.E.] [0.09] [0.55] [0.55] [0.58] [0.67] [0.09] [0.54] [0.54] [0.58] [0.67]
p-value 0.001 0.518 0.541 0.538 0.962 0.001 0.599 0.624 0.604 0.971
**** ***
Pseudo R2  0.001 0.001 0.002 0.002 0.038 0.000 0.000 0.001 0.001 0.037
Waldp-value 0.003 0.010 0.018 0.060 0.038 0.005 0.014 0.025 0.079 0.043
Observations 581 581 581 581 581 581 581 581 581 581
Significance Code: **** 0.1%; ***1%; ** 5%; * 10%
Figure 5
Logistic regression results for Phase II to Phase III advancement for projects originating at private
companies using licensing status Ato and licensing in low equity issuance period EtL as independent
variables.
Figure 5
Ajt =2) A B C D E F G H 1 3
A 0.22 0.23 0.24 0.26 0.36
[S.E.] [0.34) [0.34] [0.34] [0.34] [0.36]
p-value 0.509 0.500 0.474 0.452 0.319
Odds Ratio 1.25 1.26 1.27 1.29 1.43
2.19 2.23 2.25 2.31 2.30
[S.E.] [0.70] [0.70] [0.70] [0.71] [0.74]
p-value 0.002 0.002 0.001 0.001 0.002
Odds Ratio 8.90 9.31 9.46 10.07 10.00
Y -0.50 -0.53 -0.52 -0.52 -0.55 -0.57 -0.56 -0.57
[S.E.] [0.31] [0.32] [0.32] [0.35] [0.32] [0.32] [0.32] [0.35]
p-value 0.107 0.094 0.099 0.132 0.085 0.073 0.079 0.103
* * * * *
Odds Ratio 0.60 0.59 0.59 0.59 0.58 0.56 0.57 0.57
fl 0.20 0.21 0.20 0.22 0.23 0.17
[S.E.] [0.34] [0.34] [0.38] [0.34] [0.35] [0.38]
p-value 0.552 0.534 0.603 0.513 0.505 0.651
Odds Ratio 1.22 1.24 1.22 1.25 1.26 1.19
P MS-Mid -0.31 -0.19 -0.35 -0.20
[S.E.] [0.34] [0.40] [0.35] [0.41]
p-value 0.362 0.630 0.307 0.617
Odds Ratio 0.73 0.82 0.70 0.02
P MS-High -0.13 0.56 -0.09 0.58
[S.E.] [0.39] [0.50] [0.39] [0.51]
p-value 0.749 0.263 0.820 0.255
Odds Ratio 0.88 1.75 0.91 1.78
P Formulation 0.41 0.48
[S. E.] [0.32] [0.32]
p-value 0.192 0.129
Odds Ratio 1.51 1.62
P Bologic -0.39 -0.51
[S. E.] [0.35] [0.37]
p-value 0.272 0.168
Odds Ratio 0.68 0.60
TherCodes N N N N Y N N N N Y
a intercept -1.30 -0.88 -0.89 -0.68 -0.56 -1.34 -0.89 -0.90 -0.68 -0.48
[S.E.] [0.13] [0.29] [0.29] [0.40] [0.59] [0.13] [0.28] [0.29] [0.40] [0.59]
p-value 0.000 0.002 0.002 0.085 0.341 0.000 0.002 0.002 0.090 0.423
*** ** ** * **** ***. *** *
Pseudo R2  0.001 0.007 0.008 0.010 0.072 0.026 0.033 0.034 0.037 0.096
Wald p-value 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Observations 395 395 395 395 395 395 395 395 395 395
Si gnif i cance Code: **** 0.1%; *** 1%; ** 5%; * 10%
Figure 6
Logistic regression results for Phase II to Phase III advancement for projects originating at small public
companies using licensing status Ato and licensing in low equity issuance period E tL as independent
variables.
Figure 6
A 1(4=2) A B C D E F G H 1 3
A 0.47 0.47 0.47 0.49 0.56
[s.E.] [0.27] [0.27] [0.27] [0.28] [0.30]
p-value 0.085 0.086 0.085 0.076 0.060
Odds Ratio 1.60 1.60 1.60 1.64 1.75
0.99 0.99 0.99 0.94 1.00
[S.E.] [0.46] [0.46] [0.46] [0.47] [0.50]
p-value 0.032 0.031 0.032 0.046 0.046
** ** ** ** **
Odds Ratio 2.69 2.70 2.69 2.55 2.73
Y -0.06 -0.14 0.00 -0.09 -0.12 -0.20 -0.07 -0.17
[S.E.] [0.55] [0.55] [0.56] [0.61] [0.54] [0.55] [0.56] [0.60]
p-value 0.917 0.797 0.997 0.879 0.828 0.714 0.901 0.778
Odds Ratio 0.94 0.87 1.00 0.91 0.89 0.82 0.93 0.84
TT 0.37 0.36 0.45 0.36 0.35 0.44
[S.E.] [0.24] [0.24] [0.26] [0.24] [0.24] [0.26]
p-value 0.123 0.133 0.085 0.128 0.139 0.088
* *
Odds Ratio 1.44 1.43 1.57 1.43 1.42 1.56
P MS-Md -0.63 -0.18 -0.59 -0.10
[S.E.] [0.29] [0.36] [0.29] [0.36]
p-value 0.026 0.616 0.039 0.777
** **
Odds Ratio 0.53 0.84 0.55 0.90
P MS-High -0.67 0.04 -0.61 0.10
[S.E.] [0,37] [0.50] [0.37] [0.50]
p-value 0.073 0.939 0.100 0.837
Odds Ratio 0.51 1.04 0.54 1.11
6 Formulation 0.33 0.29
[S.E.] [0.31] [0.31]
p-value 0.290 0.356
Odds Ratio 1.40 1.33
P Biologic -0.20 -0.24
[S.E.] [0.29] [0.29]
p-value 0.495 0.415
Odds Ratio 0.82 0.79
TherCodes N N N N Y N N N N Y
a intercept -1.02 -0.96 -0.99 -0.59 -0.45 -0.99 -0.88 -0.90 -0.53 -0.36
[S.E.] [0,12] [0.54] [0.54] [0.57] [0.70] [0.11] [0.53] [0.53] [0.56] [0.70]
p-va/ue 0.000 0.073 0.066 0.295 0.523 0.000 0.100 0.092 0.349 0.608
*** * * **** *
Pseudo R2 0.006 0.006 0.010 0.020 0.070 0.009 0.009 0.013 0.022 0.071
Wald p-value 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Observations 433 433 433 433 433 433 433 433 433 433
Significance Code: **** 0.1%; *** 1%; ** 5%; * 10%
Figure 7
Logistic regression results for Phase III to Launch advancement for projects originating at private
companies using licensing status Atoand licensing in low equity issuance period EtL as independent
variables.
Figure 7
A,(t =3) A B C D E F G H I j
0.41 0.41 0.56 0.60 1.22
[S.E.] [0.57] [0.57] [0.60] [0.61] [0.76]
p-value 0.479 0.479 0.350 0.323 0.112
Odds Ratio 1.50 1.50 1.76 1.82 3.37
0.10 0.11 0.18 0.29 0.31
[S.E.] [1.12] [1.13] [1.14] [1.15] [1.36]
p-value 0.929 0.924 0.877 0.801 0.818
Odds Ratio 1.11 1.11 1.19 1.34 1.37
Y -0.03 -0.20 -0.14 0.20 -0.03 -0.16 -0.13 0.08
[S.E.] [0.56] [0.60] [0.61] [0.76] [0.57] [0.60] [0.61] [0.74]
p-value 0.961 0.743 0.823 0.795 0.956 0.784 0.835 0.915
Odds Ratio 0.97 0.82 0.87 1.22 0.97 0.85 0.88 1.08
0.57 0.54 0.42 0.43 0.40 0.23
[SE.] [0.60] [0.60] [0.74] [0.57] [0.57] [0.71]
p-value 0.340 0.368 0.565 0.453 0.488 0.743
Odds Ratio 1.77 1.71 1.53 1.53 1.49 1.26
MS-Mid 0.02 -0.66 0.01 -0.40
[S.E.] [0.71] [0.92] [0.71] [0.90]
p-value 0.979 0.469 0.992 0.660
Odds Ratio 1.02 0.52 1.01 0.67
MS-High 0.51 0.72 0.48 0.76
[S.E.] [0.78] [0.96] [0.78] [0.97]
p-value 0.514 0.450 0.538 0.434
Odds Ratio 1.66 2.06 1.61 2.14
6 Formulatbn -1.01 -0.90
[S. E.] [0.87] [0.85]
p-value 0.246 0.289
odds Ratio 0.36 0.41
P Biologic -2.20 -2.02
[S.E.] [1.31] [1.25]
p-value 0.091 0.106
odds Ratio 0.11 0.13
TherCodes N N N N Y N N N N Y
a intercept -1.79 -1.77 -1.83 -2.01 -2.35 -1.71 -1.69 -1.70 -1.85 -2.26
[S.E.] [0.28] [0.51] [0.51] [0.76] [1.41] [0.25] [0.49] [0.49] [0.73] [1.40]
p-value 0.000 0.000 0.000 0.008 0.097 0.000 0.001 0.000 0.012 0.105
**** ****. **** *** * **** ****. **** **
Pseudo R2  0.004 0.004 0.012 0.019 0.229 0.000 0.000 0.005 0.011 0.207
Waldp-value 0.000 0.000 0.000 0.000 0.016 0.000 0.000 0.000 0,000 0.011
Observations 130 130 130 130 130 130 130 130 130 130
Significance Code: **** 0.1%; *** 1%; ** 5%; * 10%
Figure 8
Logistic regression results for Phase III to Launch advancement for projects originating at small public
companies using licensing status Atoand licensing in low equity issuance period Et, as independent
variables.
Figure 8
A(t<p=3) A B C D E F G H I
0.23 0.23 0.21 0.15 0.41
[S.E.] [0.36] [0.36] [0.36] [0.37] [0.41]
p-value 0.522 0.512 0.565 0.689 0.307
Odds Ratio 1.26 1.26 1.23 1.16 1.51
0.95 0.95 0.76 0.77 1.13
[S.E.] [0.45] [0.45] [0.46] [0.47] [0.52]
p-value 0.034 0.033 0.098 0.099 0.031
** ** *4 * **
Odds Ratio 2.58 2.59 2.14 2.16 3.08
Y -0.27 -0.29 -0,28 -0.19 -0.27 -0.30 -0.26 -0.15
[S.E.] [0.59] [0.60] [0.61] [0.67] [0.60] [0.60] [0.62] [0.68]
p-value 0.648 0.625 0.649 0.779 0.645 0.623 0.646 0.832
Odds Ratio 0.76 0.74 0.76 0.83 0.76 0.74 0.75 0.86
1 0.93 0.89 0.96 0.83 0.80 0.84
[S.E.] [0,35] [0.36] [0.39] [0.36] [0.36] [0.40]
p-value 0.009 0.013 0.013 0.020 0.028 0.035
***-4 ** ** ** **. **s
Odds Ratio 2.52 2.43 2.62 2.30 2.22 2.31
P MS-Mid 1.14 1.53 1.16 1.63
[S.E.] [0.57] [0.62] [0.57] [0.64]
p-value 0.043 0.014 0.041 0.010
Odds Ratio 3.14 4.60 3.18 5.12
P MS-High 0.58 0.91 0.57 0.91
[S.E.] [0.67] [0.73] [0.67] [0.74]
p-value 0.387 0.212 0.399 0.220
Odds Ratio 1.79 2.49 1.77 2.49
P Formulation -0.59 -0.64
[S.E.] [0.56] [0.57]
p-value 0.293 0.262
Odds Ratio 0.56 0.53
P Biologic -0.55 -0.61
[S.E.] [0.44] [0.44]
p-value 0.209 0.169
Odds Ratio 0.58 0.54
TherCodes N N N N Y N N N N Y
Lintercept -1.63 -1.39 -1.67 -2.51 -2.68 -1.70 -1,45 -1.68 -2.54 -2.72
[S.E.] [0.21] [0.57] [0.60] [0.79] [1.00] [0.19] [0.57] [0.59] [0.79] [1.00]
p-value 0.000 0.016 0.005 0.002 0.007 0.000 0.012 0.005 0.001 0.007
Pseudo R2  0.002 0.003 0.033 0.058 0.167 0.019 0.019 0.043 0.069 0.182
Wad p-value 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Observations 241 241 241 241 241 241 241 241 241 241
Significance Code: **** 0.1%; *** 1%; ** 5%; * 10%
Figure 9
Logistic regression results for Phase I to Phase II advancement for licensed projects originating at private
companies using equity issuance during the licensing quarter EI(QtL) as an independent continuous
variable.
A( A B C D E
A' -9.81E-06 -6.41E-05 -1.08E-04 -1.32E-04 -3.09E-04
[S.E.] [0.00] [0.00] [0.00] [0.00] [0.00]
p-value 0.963 0.778 0.642 0.585 0.346
Y -1.45 -1.54 -1.35 -1.03
[S.E.] [0.88] [0.69] [0.91] [1.29]
p-value 0.099 0.083 0.138 0.424
* *
Odds Ratio 0.24 0.21 0.26 0.36
It 16.95 17.29 20.33
[SE.] [2400.00] [2400.00] [6523.00]
p-value 0.994 0.994 0.998
Odds Ratio 2.30E+07 3.23E+07 6.75E+08
P MS-Md 
-1.54 -1.46
[S. E.] [1.23] [1.56]
p-value 0.209 0.347
Odds Ratio 0.21 0.23
P MS-Hgh -0.72 -0.18
[SE.] [1.33] [2.20]
p-value 0.588 0.935
Odds Ratio 0.49 0.84
P Formulation -0.78
[S. E.] [1.26]
p-value 0.536
Odds Ratio 0.46
P Biologic 0.59
[S.E.] [1.03]
p-value 0.565
Odds Ratio 1.81
TherCodes N N N N Y
a intercept 0.11 1.44 1.58 2.68 18.58
[S.E.] [0.61] [1.06] [1.08] [1.59] [6523.00]
p-value 0.855 0.172 0.144 0.091 0.998
*
0.000 0.050 0.077 0.118 0.268
0.960 0.430 0.550 0.560 0.000
46 46 46 46 46
Significance Code: **** 0.1%; *** 1%; **5%; * 10%
Figure 10
Logistic regression results for Phase I to Phase II advancement for licensed projects originating at small
public companies using equity issuance during the licensing quarter EI(QtL) as an independent
continuous variable.
A,(< =1) A B C D E
1.51E-04 1.51E-04 1.51E-04 1.50E-04 2.18E-04
[S.E.] [0.00] [0.00] [0.00] [0.00] [0.00]
p-value 0.447 0.447 0.446 0.458 0.402
y -0.08 -0.07 -0.10 -0.75
[S.E.] [1.03] [1.04] [1.05] [1.39]
p-value 0.935 0.943 0.921 0.592
odds Ratio 0.92 0.93 0.90 0.47
1T -0.03 -0.07 -0.04
[S.E.] [0.54] [0.55] [0.64]
p-value 0.949 0.898 0.945
Odds Ratio 0.97 0.93 0.96
fMS-Mid -0.41 0.37
[S.E.] [0.82] [1.03]
p-value 0.618 0.716
odds Ratio 0.66 1.45
PMS-High -0.30 1.42
[S.E.] [0.96] [1,28]
p-value 0.695 0.266
odds Ratio 0.69 4.15
f Formulation -0,10
[S.E.] [1,37]
p-value 0.939
Odds Ratio 0.90
ft Biologic 0.81
[S.E.] [0.64]
p-value 0.209
odds Ratio 2.24
Th erCodes N N N N Y
aintercept -0.40 -0.32 -0.32 0.09 -1.35
[S.E.] [0.48] [1,09] [1.09] [1.37] [2.13]
p-value 0.406 0.770 0.769 0.950 0.527
0.006 0.006 0.006 0.008 0.159
0.710 0.870 0.950 0.990 1.000
75 75 75 75 75
Significance Code: **** 0.1%; *** 1%; ** 5%; * 10%
Figure 11
Logistic regression results for Phase II to Phase III advancement for licensed projects originating at
private companies using equity issuance during the licensing quarter EI(Qt as an independent
continuous variable.
A,( = 2) A B C D E
-6.15E-04 -6.35E-04 -6.36E-04 -6.41E-04 -6.31E-04
[S.E.] [0.00] [0.00] [0.00] [0.00] [0.00]
p-value 0.023 0.020 0.020 0.021 0.114
** ** ** **
Y 1.18 1.23 1.29 20,61
[S.E.] [1.16] [1.17] [1.18] [9537.00]
p-value 0.310 0.292 0.275 0.998
Odds Ratio 3.26 3.43 3.65 8.93E+08
-0.53 -0.58 -18.91
[S.E.] [1.26] [1.26] [8431.00]
p-value 0.676 0.645 0.998
Odds Ratio 0.59 0.56 6.13E-09
P MS-Mid 0.71 0.90
[S.E.] [1.28] [1.75]
p-value 0.582 0.609
Odds Ratio 2.03 2.45
P MS-Igh 0.56 36.90
[S.E.] [1.41] [9511.00]
p-value 0.693 0.997
Odds Ratio 1.74 1.06E+16
P Formulation 37.91
[S.E.] [8709.00]
p-value 0.997
Odds Ratio 2.91E+16
P Biologic 0.26
[S.E.] [1.10]
p-value 0.816
Odds Ratio 1.29
TherCodes N N N N V
a intercept 0.29 -0.71 -0.71 -1.36 -58.93
[S.E.] [0.64] [1.20] [1.20] [1.72] [2.1E+04]
p-value 0.652 0.553 0.554 0.428 0.998
0.095 0.116 0.119 0.124 0.612
0.001 0.003 0.008 0.032 0.000
55 55 55 55 55
Si gnifi cance Code: **** 0.1%; *** 1%; ** 5%; * 10%
Figure 12
Logistic regression results for Phase II to Phase III advancement for licensed projects originating at small
public companies using equity issuance during the licensing quarter EI(Qt) as an independent
continuous variable.
A, = 2) A B C D E
L -1.66E-04 -1.23E-04 -1.30E-04 -1.34E-04 -7.59E-05
[S.E.] [0.00] [0.00] [0.00] [0.00] [0,00]
p-value 0.445 0.572 0.552 0.547 0.785
y 15.98 16.08 16.10 19.78
[S.E.] [1385.00] [1385.00] [1374.00] [6107.00]
p-value 0.991 0.991 0.991 0.997
Odds Ratio 8.71E+06 9.63E+06 9.82E+06 3.89E+08
1T -0.42 -0.41 -0.51
[S.E.] [0.57] [0.58] [0.76]
p-value 0.468 0.482 0.506
Odds Ratio 0.66 0.66 0.60
/ MS-Mi 0.45 0.29
[S.E.] [0.77] [1.30]
p-value 0.564 0.820
Odds Ratio 1.56 1.34
PMS-HIgh -0.46 -0.07
[S.E.] [1.08] [2.30]
p-value 0.673 0.977
Odds Ratio 0.63 0.94
A Formulation 0.99
[S.E.] [1.43]
p-value 0.488
Odds Ratio 2.70
SBiologc 0.53
[S.E.] [0.67]
p-value 0.428
Odds Ratio 1.71
TherCodes N N N N Y
aintercept -0.21 -16.21 -16.19 -16.48 -19.80
[S.E.] [0.50] [1385.001 [1385.00] [1374.00] [6107.00]
p-value 0.679 0.991 0.991 0.990 0.997
0.006 0.034 0.039 0.055 0.308
0.067 0.000 0.000 0.500 0.000
71 71 71 71 71
Significance code: **** 0.1 *1%j ** 5%; * 10%
Figure 13
Logistic regression results for Phase III to Launch advancement for licensed projects originating at private
companies using equity issuance during the licensing quarter EI(QtL) as an independent continuous
variable.
<p =3) A B C D E
1.53E-05 4.23E-05 5.45E-06 3.67E-04 1.29E-03
[S.E.] [0.00] [0.00] [0.00] [0.00] [0.00]
p-value 0.964 0.908 0.988 0.488 0.548
Y -0.99 -0.92 -1.62 -4.32
[S.E.] [1.08] [1.08] [1.49] [53510.00]
p-value 0.357 0.395 0.276 1.000
Odds Ratio 0.37 0.40 0.20 0.01
.Tr 
-14.95 -16.77 21.55
[S.E.] [2400.00] [6523.00] [62100,00]
p-value 0.995 0.998 1.000
Odds Ratio 3.22E-07 5.21E-08 2.29E+09
A MS-Mid 18.26 -0.38
[S.E.] [2750.00] [54310.00]
p-value 0.995 1.000
Odds Ratio 8.52E+07 0.68
P MS-High 17.00 14.78
[S.E.] [2750.00] [85070.00]
p-value 0.995 1.000
Odds Ratio 2.42E+07 2623447.89
P Formulation -18.78
[S.E.] [30110.00]
p-value 1.000
Odds Ratio 6.98E-09
P Biolagic -0.95
[S.E.] [87150.00]
p-value 1.000
Odds Ratio 0.39
TherCodes N N N N Y
aintercept 
-1.42 -0.77 -0.70 -18.59 -1.59
[S.E.] [0.85] [1.09] [1.10] [2750.00] [95090.00]
p-value 0.094 0.481 0.524 0.995 1.000
0.000 0.033 0.046 0.186 0.872
0.021 0.052 0.130 0.000 0.000
25 25 25 25 25
Significance Code: **** 0.1%; *** 1%; ** 5%; * 10%
Figure 14
Logistic regression results for Phase III to Launch advancement for licensed projects originating at small
public companies using equity issuance during the licensing quarter EI(QtL as an independent
continuous variable.
CD, = 3) A B C D E
-6.48E-04 -6.71E-04 -5.80E-04 -6.09E-04 -1.48E-03
[S.E.] [0.00] [0.00] [0.00] [0.00] [0,00]
p-value 0.028 0.030 0.058 0.062 0.030
** ** * * **
y 16.11 16.25 16.07 60.27
[S.E.] [1611.00] [1596.00] [1588.00] [8407.00]
p-value 0.992 0.992 0.992 0.994
Odds Ratio 9.92E+06 1.14E+07 9.53E+06 1.50E+26
0.67 0.74 1.51
[S.E.] [0.65] [0.67] [1.19]
p-value 0.300 0.269 0.204
odds Ratio 1.96 2.10 4.53
PMS-Mid 1.47 20.36
[S.E.] [1.15] [3342.00]
p-value 0.200 0.995
Odds Ratio 4.35 6.95E+08
P MS-H-igh 0.71 18.42
[S.E.] [1.36] [3342.00]
p-value 0.603 0.996
Odds Ratio 2.03 9.99E+07
P Formulation -0.23
[S.E.] [1.42]
p-value 0.873
Odds Ratio 0.80
P Biologc 0.20
[S.E.] [1.16]
p-value 0.864
Odds Ratio 1.22
TherCodes N N N N Y
aintercept -0.35 -16.34 -16.85 -17.82 -80.51
[S.E.] [0.50] [1611.00] [1596.00] [1588.00] [10210.00]
p-value 0.489 0.992 0.992 0.991 0.994
0.085 0.114 0.127 0.161 0.554
0.000 0.000 0.000 0.004 0.000
76 76 76 76 76
Significance Code: **** 0.1%; *** 1%; ** 5%; * 10%
